Earnings ·
Intellia reports $127.5M Q3 loss, secures up to $400M term loan with OrbiMed
NTLAIntellia Therapeutics, Inc.
Intellia Therapeutics reported a net loss of $127.5 million for the third quarter ended September 30, 2026, compared to a $101.3 million loss in the prior-year period. The company also announced it entered into a non-dilutive senior secured term loan facility with OrbiMed for up to $400 million to provide financial flexibility ahead of its planned commercial launch. Cash and equivalents stood at $614.8 million as of September 30, 2026. The company completed enrollment in the MAGNITUDE-2 Phase 3 trial for ATTRv-PN and advanced enrollment in the MAGNITUDE trial for ATTR-CM. Intellia Therapeutics is a biopharmaceutical company focused on developing CRISPR gene editing therapies.